The antigen rapid diagnostic test (Ag-RDT) is a useful diagnostic tool for the detection and management of COVID-19 spread. Global SARS-CoV-2 variant outbreaks have highlighted the need for a test capable of detecting SARS-CoV-2 variants with high sensitivity and a low limit of detection. This study aimed to develop and evaluate, both analytically and clinically, an antigen rapid diagnostic test (the Kestrel^TM COVID-19 Ag Rapid Test) for professional use. A lateral flow immunoassay-based diagnostic test kit was developed, and various aspects of its analytical performance were evaluated. This test kit was clinically evaluated by two independent laboratories and showed closely related results of 96.49% and 98.33% of sensitivity, 100% and 100% of specificity, and 99.01% and 99.44% of accuracy, respectively. A limit of detection was observed at values as low as 0.156 ng/mL for recombinant SARS-CoV-2 nucleocapsid protein. Moreover, the test kit successfully detected the recombinant SARS-CoV-2 nucleocapsid protein (NP) of wild-type, Alpha-, Beta-, Gamma-, Delta-, Epsilon-, Kappa-, and Omicron-variants as positive results. Therefore, the Kestrel^TM COVID-19 Ag Rapid Test may have potential use for effective COVID-19 screening, surveillance, and infection control in a variety of global SARS-CoV-2 variant outbreaks.

The development of effective wound dressings remains a critical challenge in medical treatments, requiring materials that promote healing, minimize infection, and enhance tissue regeneration. This study evaluated the wound-healing potential of sericin-based film-forming gels. Six formulations were developed by combining varying concentrations of sericin, a protein derived from silk cocoons, with polyvinyl alcohol (PVA). These formulations were evaluated for physical properties including drying time, pH, spreadability, stability, swelling ratio, flexibility, and adhesion. Film-forming gel is an attractive option for wound dressing due to its flexibility, adhesion, and infrequent reapplication. The F4 formulation (1% sericin) demonstrated superior performances in drying time, spreadability, stability, swelling ratio, flexibility, and skin adhesion, was easy to apply, and formed a stable film on drying. Biological evaluations showed that F4 exhibited excellent compatibility with skin fibroblast cells, maintained a suitable pH, and significantly promoted cell proliferation and migration. The F4 formulation also demonstrated anti-inflammatory effects by inhibiting iNOS expression and nitric oxide production, offering mechanical stability, biological activity, and ease of use with significant potential for treating acute and chronic wounds.

Curcuminoids, namely curcumin, demethoxycurcumin, and bisdemethoxycurcumin, are the major active compounds found in Curcuma longa L. (turmeric). Although their suppressive effects on bone resorption have been demonstrated, their pharmacokinetic disadvantages remain a concern. Herein, we utilized solid dispersion of a curcuminoid-rich extract (CRE), comprising such curcuminoids, to prepare CRE-SD; subsequently, we performed liposome encapsulation of the CRE-SD to yield liposomal CRE-SD. In vitro release assessment revealed that a lower cumulative mass percentage of CRE-SD was released from liposomal CRE-SD than from CRE-SD samples. After culture of murine RANKL-stimulated RAW 264.7 macrophages, our in vitro examinations confirmed that liposomal CRE-SD may impede osteoclastogenesis by suppressing p65 and IκBα phosphorylation, together with nuclear translocation and transcriptional activity of phosphorylated p65. Blind docking simulations showed the high binding affinity between curcuminoids and the IκBα/p50/p65 protein complex, along with many intermolecular interactions, which corroborated our in vitro findings. Therefore, liposomal CRE-SD can inhibit osteoclastogenesis via the canonical NF-κB signaling pathway, suggesting its pharmacological potential for treating bone diseases with excessive osteoclastogenesis.

This study aims to analyze the neutralization ability against Omicron parental variants in five clusters of individuals with different Coronavirus disease (COVID-19) immunity backgrounds, including individuals receiving a homologous or heterologous vaccine without prior infection, recovered patients with homologous or heterologous vaccination, and recovery patients without vaccination. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) surrogate virus neutralization assay was performed on serum samples. Spearman correlation analysis showed that the percent inhibition against Omicron B.1.1.529 and BA.2 was significantly related to the period of serum collection (r = 0.730 and 0.787, p < 0.001, respectively). Very strong correlation between percent inhibition of neutralizing antibody against Omicron B.1.1.529 and BA.2 variants (r_s = 0.973, p < 0.001) was also observed. The neutralizing activity of the sera from recovery patients receiving homologous and heterologous vaccine against the wild-type, B.1.1.529, and BA.2 Omicron variants was significantly higher (p < 0.001) than that of recovery patients without vaccination. This study robustly showed that the breakthrough SARS-CoV-2 Omicron variant in individuals who received homologous and heterologous vaccines had a high level of neutralizing activity against B.1.1.529 and BA.2 parental lineage of XBB subvariants. Therefore, the next-generation COVID-19 vaccine against emerging variants is needed to improve resilience against ongoing variants, particularly for persons who have never been infected.

Objectives: This study evaluated the analytical and clinical performance of a novel NS1 rapid diagnostic test in a dengue-endemic setting in Thailand. Methods: The K-Dengue NS1 Ag test (K.Bio Sciences, Pathumthani, Thailand) was developed. Analytical performance included determination of LOD, reproducibility, and evaluation against potentially cross-reactive pathogens and interfering substances. Unlike conventional assays employing 40 nm colloidal gold, this test incorporates 80 nm gold nanospheres to enhance detection sensitivity. The LOD was determined by serial dilution of recombinant NS1 proteins representing all four dengue virus serotypes. Clinical performance was assessed using 185 archived plasma samples collected between January 2024 and February 2025 from two tertiary care hospitals in Thailand, with a commercial NS1 ELISA serving as the reference standard. Results: The K-Dengue NS1 test demonstrated serotype-specific limits of detection (LODs) for recombinant NS1 antigen, 2.9 ng/mL (DENV-1), 0.5 ng/mL (DENV-2), 25.2 ng/mL 27 (DENV-3), and 4.5 ng/mL (DENV-4). Cross-reactivity testing revealed no false positives against closely related arboviruses or common co-infections, and no interference was observed from frequently encountered pathogens or biochemical substances. In clinical evaluation, the assay achieved a sensitivity of 98.08% (51/52), a specificity of 100% (133/133), and an overall accuracy of 99.37%. Importantly, sensitivity was significantly higher in primary infections (100.00%) than in secondary infections (93.3%, p = 0.288). Conclusions: In this clinically oriented evaluation, the K-Dengue NS1 rapid test showed high specificity and good sensitivity, particularly in primary dengue infections. While the assay may be useful as part of early diagnostic workflows in comparable healthcare settings, reduced sensitivity in secondary infections indicates that negative NS1 results should be interpreted with caution and, where appropriate, supplemented with additional diagnostic methods.